Zhejiang Medicine Co., Ltd. (SHA:600216)
China · Delayed Price · Currency is CNY 15.35
+0.31 (2.06%)
Jul 16, 2025, 2:45 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
Vitamin E | 2.79B | Log In | Log In | Log In | Log In | Upgrade |
Vitamin E Growth | -19.27% | Log In | Log In | Log In | Log In | Upgrade |
Social Delivery Series | 2.24B | Log In | Log In | Log In | Log In | Upgrade |
Social Delivery Series Growth | 5.03% | Log In | Log In | Log In | Log In | Upgrade |
Vitamin A | 495.21M | Log In | Log In | Log In | Log In | Upgrade |
Vitamin A Growth | -3.71% | Log In | Log In | Log In | Log In | Upgrade |
Levofloxacin Series | 442.00M | Log In | Log In | Log In | Log In | Upgrade |
Levofloxacin Series Growth | 13.46% | Log In | Log In | Log In | Log In | Upgrade |
Vancomycin Hydrochloride | 398.87M | Log In | Log In | Log In | Log In | Upgrade |
Vancomycin Hydrochloride Growth | 4.64% | Log In | Log In | Log In | Log In | Upgrade |
Nerofloxacin Malate Series | 325.03M | Log In | Log In | Log In | Log In | Upgrade |
Nerofloxacin Malate Series Growth | 87.06% | Log In | Log In | Log In | Log In | Upgrade |
Miglitol Series | 221.82M | Log In | Log In | Log In | Log In | Upgrade |
Miglitol Series Growth | -5.58% | Log In | Log In | Log In | Log In | Upgrade |
Teicoplanin Series | 182.56M | Log In | Log In | Log In | Log In | Upgrade |
Teicoplanin Series Growth | 1.82% | Log In | Log In | Log In | Log In | Upgrade |
Progesterone Series | 76.53M | Log In | Log In | Log In | Log In | Upgrade |
Progesterone Series Growth | -22.72% | Log In | Log In | Log In | Log In | Upgrade |
Other | 622.98M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 20.74% | Log In | Log In | Log In | Log In | Upgrade |
Carotenoid | - | Log In | Log In | Log In | Log In | Upgrade |
Carotenoid Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Kolanin | - | Log In | Log In | Log In | Log In | Upgrade |
Kolanin Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Natural Vitamin E series | - | Log In | Log In | Log In | Log In | Upgrade |
Natural Vitamin E series Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Datomosan Raw Material | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
China | 5.63B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 5.35% | Log In | Log In | Log In | Log In | Upgrade |
Overseas | 3.07B | Log In | Log In | Log In | Log In | Upgrade |
Overseas Growth | -21.55% | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Offset | -907.77M | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Offset Growth | -23.49% | Log In | Log In | Log In | Log In | Upgrade |